Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Melanoma · Tumor · NKTR

Nektar Therapeutics UK

Nektar Therapeutics UK Limited

Nektar Therapeutics UK clinical programs — 32 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
455 Mission Bay Boulevard South, San Francisco, California 94158, US HQ
1990 Founded
610 Employees
Public company Type
NKTR · NYSE Ticker
Company details
Status
Public
HQ
455 Mission Bay Boulevard South, San Francisco, California 94158, US
Founded
1990
Employees
610
Programs
57
Drugs
31
Patents
423
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Nektar Therapeutics UK projects

32 ClinicalTrials.gov programs sponsored by Nektar Therapeutics UK.

Nektar Therapeutics UK has 32 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

32 programs

Clinical programs

  1. Amikacin (BAY41-6551)

    Nektar Therapeutics UK Limited

    Pneumonia

    phase 2 small molecule completed

    1 trial

  2. Amikacin inhalation solution (BAY41-6551)

    Nektar Therapeutics UK Limited

    Pneumonia

    phase 2 small molecule completed

    1 trial

  3. Avelumab

    Nektar Therapeutics UK Limited

    Locally Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  4. Bempegaldesleukin

    Nektar Therapeutics UK Limited

    Urinary Bladder Neoplasm

    phase 2 mab completed

    1 trial

  5. Dose Escalation Doublet: Combination of NKTR-214 + nivolumab

    Nektar Therapeutics UK Limited

    Melanoma

    phase 2 small molecule completed

    1 trial

  6. Dronabinol MDI

    Nektar Therapeutics UK Limited

    Migraine With Aura

    phase 2 small molecule completed

    1 trial

  7. Etirinotecan pegol

    Nektar Therapeutics UK Limited

    Anaplastic Astrocytomas

    phase 2 small molecule completed

    1 trial

  8. LY3471851

    Nektar Therapeutics UK Limited

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    2 trials

  9. LY3471851

    Nektar Therapeutics UK Limited

    Colitis, Ulcerative

    phase 2 small molecule terminated

    1 trial

  10. NKTR-102

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  11. NKTR-102

    Nektar Therapeutics UK Limited

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  12. NKTR-102 100 mg/m2

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  13. NKTR-102 145 mg/m2

    Nektar Therapeutics UK Limited

    Malignant Solid Tumor

    phase 2 small molecule completed

    1 trial

  14. NKTR-102 q14d

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  15. NKTR-181

    Nektar Therapeutics UK Limited

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    1 trial

  16. NKTR-214

    Nektar Therapeutics UK Limited

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 2 small molecule completed

    1 trial

  17. NKTR-214

    Nektar Therapeutics UK Limited

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  18. NKTR-214

    Nektar Therapeutics UK Limited

    Non-Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  19. NKTR-255

    Nektar Therapeutics UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  20. NKTR-255

    Nektar Therapeutics UK Limited

    Lung Cancer

    phase 2 small molecule active

    1 trial

  21. NKTR-262

    Nektar Therapeutics UK Limited

    Melanoma

    phase 2 small molecule terminated

    1 trial

  22. NKTR-358, Placebo

    Nektar Therapeutics UK Limited

    Alopecia Areata

    phase 2 small molecule active

    1 trial

  23. NKTR-358, Sodium Chloride 0.9% solution

    Nektar Therapeutics UK Limited

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  24. Nivolumab

    Nektar Therapeutics UK Limited

    Ependymoma

    phase 2 mab terminated

    1 trial

  25. Pegylated Irinotecan

    Nektar Therapeutics UK Limited

    Recurrent Small Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  26. Pegylated Irinotecan

    Nektar Therapeutics UK Limited

    Stage IV Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule completed

    1 trial

  27. Rezpegaldesleukin

    Nektar Therapeutics UK Limited

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  28. Rezpegaldesleukin

    Nektar Therapeutics UK Limited

    Alopecia Areata

    phase 2 small molecule active

    1 trial

  29. VB10.NEO

    Nektar Therapeutics UK Limited

    Locally Advanced or Metastatic Solid Tumours

    phase 2 mab completed

    1 trial

  30. aerosolized vancomycin or gentamicin

    Nektar Therapeutics UK Limited

    Ventilator Associated Pneumonia

    phase 2 small molecule completed

    1 trial

  31. avelumab

    Nektar Therapeutics UK Limited

    Squamous Cell Carcinoma of the Head and Neck (SCCHN)

    phase 2 small molecule terminated

    1 trial

  32. placebo

    Nektar Therapeutics UK Limited

    Opioid Induced Constipation (OIC)

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Nektar Therapeutics UK have?

32 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.